Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Abstract Background  First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations of cytotoxic chemotherapy and ICIs have included on...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto
التنسيق: مقال
اللغة:English
منشور في: BMC 2022-09-01
سلاسل:BMC Cancer
الموضوعات:
Clinical trial
Nonsquamous non–small cell lung cancer
Immune checkpoint inhibitor
Chemotherapy
Renal impairment
الوصول للمادة أونلاين:https://doi.org/10.1186/s12885-022-10056-x

الانترنت

https://doi.org/10.1186/s12885-022-10056-x

مواد مشابهة